Hemorrhoids – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Hemorrhoids, or piles, result from enlarged or varicose veins in the anus and rectum. Internal hemorrhoids develop above the dentate line and are typically painless due to their visceral innervation. The precise cause of hemorrhoids remains uncertain. Upright posture places significant pressure on rectal veins, potentially leading to bulging. Other contributing factors encompass aging, chronic constipation or diarrhea, pregnancy, heredity, straining during bowel movements, faulty bowel function from overuse of laxatives or enemas, and prolonged periods spent on the toilet, such as while reading. Hemorrhoids often exhibit no symptoms or may protrude. Hemorrhoids are generally not responsible for pruritus ani unless they are substantially prolapsed. External hemorrhoids can become thrombosed, resulting in painful, purplish swelling and, rarely, ulceration with minor bleeding, making anal cleansing challenging. Internal hemorrhoids usually present with bleeding after defecation, where blood is observed on toilet paper and occasionally in the toilet bowl. While internal hemorrhoids can be uncomfortable, they are less painful than thrombosed external hemorrhoids. Internal hemorrhoids may also lead to mucus discharge and a sensation of incomplete evacuation. Strangulated hemorrhoids occur when the protrusion and constriction block the blood supply, causing pain, potential necrosis, and ulceration. Hemorrhoids are categorized based on their presentation: grade I involves hemorrhoids that do not prolapse and appear as bulges in the anal canal with or without bleeding. Grade II hemorrhoids prolapse but reduce spontaneously. Grade III hemorrhoids require digital reduction of prolapsed tissue. Grade IV hemorrhoidal piles are irreducible. Complications of hemorrhoids may include - Blood clots in an external hemorrhoid, Skin tags are extra skin left behind when a blood clot in an external hemorrhoid dissolves, Infection of a sore on an external hemorrhoid, Strangulated hemorrhoid, where the muscles around the anus cut off blood supply to an internal hemorrhoid that has fallen through the anal opening. The primary conservative treatment for hemorrhoids includes a high-fiber diet (25 to 35 grams daily), fiber supplements, increased water intake, warm water sitz baths, and stool softeners. Prescription therapies may also be used as part of the initial treatment, with topical nitroglycerin effectively reducing rectal pain caused by thrombosed hemorrhoids. However, it is more commonly used for anal fissures. Office-based and surgical procedures can be effective for hemorrhoids that do not respond to medical therapies. Generally, the lower the grade of hemorrhoids, the more successful an office-based procedure is likely to be while recurring, and grade III or IV hemorrhoids are more amenable to excisional hemorrhoidectomy.
- In the United States, hemorrhoid disease ranks as the fourth leading outpatient gastrointestinal diagnosis, accounting for 3.3 million ambulatory care visits.
- The worldwide prevalence of hemorrhoids in the general population is approximately 4.4%, with a higher prevalence among individuals aged 45 to 65.
Thelansis’s “Hemorrhoids Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hemorrhoids treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Hemorrhoids across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Hemorrhoids Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment